幽门螺杆菌耐药初探

目的:观察幽门螺杆菌(Helicobacter pylori,H.pylori)对克拉霉素、呋喃唑酮的耐药情况,初步了解克拉霉素耐药菌株为原发耐药还是继发耐药,初步探讨抗H.pylori感染失败的原因是由于原有菌株未消灭还是由于感染了新的菌株.方法:从消化性溃疡及糜烂性胃炎患者的胃黏膜中分离培养出H.pylori共21株,利用纸片法进行药物敏感试验,观察耐药情况.应用随机扩增多态性DNA分析方法,进行菌株指纹图谱分析,确定抗H.pylori治疗前后菌株的同一性.结果:(1)21株H.pylori中有8株对克拉霉素耐药,1株对呋喃唑酮耐药,耐药率分别为38.1%和4.8%.(2)3对治疗前后配对菌株中,1例为原发性耐药(持续感染),1例为继发性耐药,另有1例为新菌株感染.结论:H.pylori对克拉霉素耐药率比较高,而对呋喃唑酮高度敏感.抗H.pylori感染失败的原因与菌株对克拉霉素原发性及继发性耐药有关.

Antibiotic resistance of Helicobacter pylori

Objective To examine the infection and bacteria resistance of Helicobacter pylori (H.pylori) to clarithromycin and furazolidone,to determine whether the antibiotic resistance is primary or secondary, and to decide if a new H.pylori infection plays a role in eradication failures. Methods Twenty one H.pylori had been isolated from human biopsy specimens, and antimicrobial susceptibility testing was performed. DNA fingerprints were generated using random amplification polymorphic DNA (RAPD) to determine the identity of H.pylori before and after the eradication therapy. Results Eight bacteria resisted against clarithromycin, and one against furazolidone, with the resistant rates 38.1% and 4.8% respectively. The number of primary antibiotic resistance, secondary resistnace and new infection was 1 for each. Conclusion Resistance to clarithromycin is more common compared with that to furazolidone. Development of primary and secondary resistance to clarithromycin occurs as a rule in eradication failures. New H.pylori infection plays a role in eradication failures.